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Summary
 
Although several adhesion molecules expressed on leukocytes (
 
b
 
1 and 
 
b
 
2 integrins, platelet en-
dothelial cell adhesion molecule 1 [PECAM-1], and CD47) and on endothelium (intercellular
adhesion molecule 1, PECAM-1) have been implicated in leukocyte transendothelial migra-
tion, less is known about the role of endothelial lateral junctions during this process. We have
shown previously (Read, M.A., A.S. Neish, F.W. Luscinskas, V.J. Palambella, T. Maniatis, and
T. Collins. 1995. 
 
Immunity.
 
 2:493–506) that inhibitors of the proteasome reduce lymphocyte and
neutrophil adhesion and transmigration across TNF-
 
a
 
–activated human umbilical vein endothelial
cell (EC) monolayers in an in vitro flow model. The current study examined EC lateral junction
proteins, principally the vascular endothelial (VE)–cadherin complex and the effects of protea-
some inhibitors (MG132 and lactacystin) on lateral junctions during leukocyte adhesion, to gain a
better understanding of the role of EC junctions in leukocyte transmigration. Both biochemical
and indirect immunofluorescence analyses of the adherens junction zone of EC monolayers re-
vealed that neutrophil adhesion, not transmigration, induced disruption of the VE–cadherin
complex and loss of its lateral junction localization. In contrast, PECAM-1, which is located at
lateral junctions and is implicated in neutrophil transmigration, was not altered. These findings
identify new and interrelated endothelial-dependent mechanisms for leukocyte transmigration
that involve alterations in lateral junction structure and a proteasome-dependent event(s).
 
L
 
ocalized leukocyte accumulation is the cellular hall-
mark of inflammation. Although this has been recog-
nized for more than a century, it is only in the past decade
that the role of the endothelium has been appreciated. The
notion that the vascular endothelium actively participates
in leukocyte recruitment initially gained support from in
vitro studies demonstrating that treatment of cultured en-
dothelium with inflammatory cytokines TNF-
 
a
 
 or IL-1,
and certain Gram-negative bacterial endotoxin could “acti-
vate” the endothelium to become adhesive for blood leu-
kocytes and cell lines (1–3). Subsequently, the work of
many investigators has identified and molecularly cloned
several such endothelial cell (EC)
 
1
 
 adhesion molecules and
their cognate ligands on leukocytes, which support leuko-
cyte adhesion to endothelium.
Recent reports have shown that the proteasome pathway
is involved in activation of NF-
 
k
 
B, which is a transcription
factor necessary for activation of EC gene transcription
of E-selectin (CD62E), intercellular adhesion molecule 1
(ICAM-1) (CD54), and vascular cell adhesion molecule 1
(VCAM-1) (CD106) (4). Small peptide aldehyde inhibitors
(MG132, MG115) of the proteasome can dramatically re-
duce TNF-
 
a
 
–induced expression of E-selectin, VCAM-1,
and ICAM-1 in human umbilical vein ECs (4). Function-
ally, neutrophil adhesion was reduced by 50%, and transmi-
gration was reduced by 
 
.
 
60%. Live-time video micros-
copy showed that many adherent neutrophils had flattened
and extended pseudopods into the EC junctions, but were
 
1
 
Abbreviations used in this paper:
 
 ALLM, 
 
N
 
-acetyl-leucinyl-leucinyl-
methional; DPBS, Dulbecco’s phosphate-buffered saline; EC, endothelial
cell; HUVEC, human umbilical vein endothelial cell; HSA, human serum
albumin; ICAM, intercellular adhesion molecule; PECAM-1, platelet en-
dothelial cell adhesion molecule 1; TBS, Tris-buffered saline; VCAM 1,
vascular cell adhesion molecule 1.
 
This manuscript was presented in abstract form at the IX International
Vascular Biology Meeting held in Seattle, WA on September 4–9, 1996,
and at Experimental Biology ’97 held in New Orleans, LA on April 6–9,
1997.
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unable to transmigrate. This result raises the possibility that
the proteasome regulates an essential endothelial-depen-
dent component(s) during transendothelial passage.
In light of our previous observations that proteasome in-
hibitors prevent firmly adherent neutrophils from penetrat-
ing between endothelial cell–cell lateral junctions, we rea-
soned that the function of endothelial cell-to-cell lateral
junctions may be critical during the process of leukocyte
transmigration. The molecular structure and organization of
endothelial cell–cell lateral junctions has been reviewed (5–7).
We focused our attention on the adherens type junctions
which appear to serve as a focal point for the connections
between the EC plasma membrane and its underlying
actin-cytoskeleton complex. The adherens type junctions
contain cadherins (for review see reference 7), a family of
single-span transmembrane glycoproteins which directly as-
sociate with structural components of the cytoskeleton and
mediate Ca
 
2
 
1
 
-dependent cell–cell adhesion in a homotypic
fashion. Cadherin-5, also termed vascular endothelial (VE)–
cadherin, is specific to vascular endothelium and localizes
exclusively to lateral junctions of intact, confluent endothe-
lium (8, 9). A recent study (8) has revealed that VE–cadherin
associates with the cytosolic proteins 
 
a
 
- and 
 
b
 
-catenins to
form a complex and organize at nascent endothelial cell-to-
cell contacts. Plakoglobin (also named 
 
g
 
-catenin) associated
with VE–cadherin and 
 
a
 
- and 
 
b
 
-catenins at cell-to-cell con-
tacts, through an undefined mechanism(s), only as EC ap-
proached confluence. p120 (p120
 
cas
 
), initially identified as
one of several substrates of the tyrosine kinase pp60
 
src
 
 (10,
11), and a closely associated molecule termed p100 also
have been reported to associate with 
 
a
 
- and 
 
b
 
-catenins and
VE-cadherin in umbilical vein endothelium (12). That the
VE–cadherin complex is dynamic and involved in regulat-
ing cell-to-cell contact is suggested by wounding (8) or
Ca
 
2
 
1
 
 depletion (5) experiments where VE-cadherin and
plakoglobin rapidly and reversibly retract from the endo-
thelial lateral junctions.
To better understand the molecular basis of inhibition of
neutrophil transmigration by proteasome inhibitors and the
potential role of the components of the EC adherens junc-
tions, we have evaluated the effects of two structurally differ-
ent proteasome inhibitors, MG132 and lactacystin (13), on the
association of VE–cadherin with 
 
a
 
-, 
 
b
 
-, and 
 
g
 
-catenin (plako-
globin), and p120/p100 in 6-h TNF-
 
a
 
–activated EC using
both indirect immunofluorescence microscopy and immuno-
precipitation followed by immunoblotting. Second, we have
coincubated human neutrophils with control or protea-
some inhibitor–treated TNF-
 
a
 
–activated endothelium, and
evaluated the staining patterns and biochemical association
of members of the VE-cadherin complex, and as a control,
platelet endothelial cell adhesion molecule 1 (PECAM-1;
CD31), which has been shown previously to colocalize to
EC lateral junctions (14) and has been implicated in leuko-
cyte transmigration in in vivo and in vitro studies (15). The
results of these experiments suggest that novel endothelial-
dependent mechanisms regulate neutrophil transmigration
which involves structural alterations of the VE–cadherin
complex, as well as a proteasomal-dependent step(s).
 
Materials and Methods
 
Materials
 
Dulbecco’s phosphate-buffered saline (DPBS) with Ca
 
2
 
1
 
 and
Mg
 
2
 
1
 
, DPBS, M199, DMEM, RPMI-1640 with 25 mM Hepes,
and 1 M solution of Hepes were purchased from BioWhittaker
Bioproducts (Walkersville, MD). Human 
 
r
 
TNF-
 
a
 
 (produced in
 
Escherichia coli
 
) was the gift of Dr. Baker (Genentech Inc., South
San Francisco, CA), and a concentration of 25 ng/ml gave maxi-
mal response and contained 
 
,
 
10 pg/ml of endotoxin as reported
previously (16). The proteasome inhibitors, MG132 (carboben-
zoxyl-leucinyl-leucinyl-leucinal-H) and lactacystin were the gift
of Dr. J. Adams (ProScript, Inc., Cambridge, MA). Each inhibi-
tor was dissolved in DMSO at 40 mM and stored at 
 
2
 
80
 
8
 
C. For
use in experiments, aliquots of inhibitors were thawed at 37
 
8
 
C
and diluted directly into appropriate culture media, or as other-
wise noted in the text. Calpain inhibitor II (also abbreviated as
ALLM [
 
N
 
-acetyl-leucinyl-leucinyl-methional]) and aprotinin were
purchased from Calbiochem Corp. (La Jolla, CA). EDTA, Protein–G
Sepharose, PMSF, leupeptin, DMSO, BSA, and Hepes were pur-
chased from Sigma Chemical Co. (St. Louis, MO). Human se-
rum albumin (HSA) was obtained from Baxter Healthcare Corp.
(Glendale, CA).
 
mAbs
 
The following murine mAbs have been reported previously:
anti–E-selectin (H4/18 or 7A9, each an IgG
 
1
 
; reference 16), anti–
ICAM-1 (Hu5/3, IgG
 
1
 
; reference 17), anti–VCAM-1 mAb E1/6
(IgG
 
1
 
; reference 18), anti–PECAM-1 (obtained from Iowa Hy-
bridoma Bank, Iowa City, IA, or from Immunotech, Inc., West-
brook, ME), and anti–HLA-A,B (W6/32, IgG
 
2a
 
) mAb (19).
These mAb were used as hybridoma culture supernatant fluid for
surface immunofluorescence assays and as pure IgG for immuno-
fluorescence microscopy, immunoprecipitations, and Western blot-
ting. Murine mAb directed to VE–cadherin (clone TEA1/31,
IgG
 
1
 
) was purchased from Immunotech Inc. or from BIODE-
SIGN Intl. (Kennebunk, ME). Murine mAb directed to plako-
globin (clone PG5.1, IgG
 
2b
 
) was purchased from BIODESIGN
Intl. Murine mAb to 
 
a
 
- and 
 
b
 
-catenins and p120 (clone 5, 14,
and 98, respectively; all IgG
 
1
 
) were purchased from Transduction
Labs. (Lexington, KY). A second mAb to 
 
a
 
-catenin (Zymed, S.
San Francisco, CA) was used for immunofluorescence studies.
 
Cell Culture
 
ECs were isolated from two to five umbilical cord veins,
pooled, and established as detailed (19). Primary human umbilical
vein endothelial cell (HUVEC) cultures were serially passaged (1:
3 split ratio) and maintained in M199 containing 10% FCS, EC
growth factor, porcine intestinal heparin, and antibiotics.
 
Experimental Protocols.
 
For immunofluorescence staining as-
says, ECs (passage 1–2) were plated at confluent density on 4-well
chamber glass slides (Lab-Tek; Nunc, Inc., Naperville, IL) until 2 d
after confluent. For flow assays, ECs were plated at confluence on
human fibronectin (2 
 
m
 
g/cm
 
2
 
)-coated 25-mm glass coverslips
(20), and used 3 d later. For quantitative surface immunofluores-
cence assays, ECs were plated on fibronectin-coated microtiter
plates (C96; Costar, Cambridge, MA), and used 2–3 d after con-
fluence. For immunoprecipitation assays, EC were plated on 0.1%
gelatin-coated 100-mm diameter plastic petri dishes (Costar), and
used 3 d after attaining confluence. EC monolayers were not ma-
nipulated or fed for 48 h before use. 
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Leukocyte Isolation
 
Human neutrophils were purified from whole blood of volun-
teer donors as previously detailed (19). Isolated neutrophils (94%
pure) were resuspended in cold DPBS containing 0.75 mM Ca
 
2
 
1
 
,
0.75 mM Mg
 
2
 
1
 
, and 0.2% HSA (assay buffer).
 
Endothelial–Leukocyte Interactions in a Parallel-plate
Flow Chamber
 
The parallel-plate flow chamber used in this study has been de-
scribed in detail (20–22). A wall shear stress of 1.8 dynes/cm
 
2
 
 was
achieved with a flow rate of 0.85 ml/min (20). EC monolayers
were assayed for leukocyte adhesion and transmigration under
flow conditions as before (16, 20).
 
Immunofluorescence Assays
 
Quantitative surface immunofluorescence assays for adhesion
molecule expression on EC were performed in triplicate wells as
reported previously (17) using appropriate primary mAb–detected
FITC-conjugated goat anti–mouse (F(ab
 
9
 
)
 
2
 
, 1:50 dilution; Caltag
Labs., S. San Francisco, CA).
 
Indirect Immunofluorescence Staining.
 
Indirect immunofluores-
cence staining of endothelial surface molecules was performed us-
ing the protocol of Gerritsen et al. (23). In brief, confluent EC
in 4-well chambers were activated as detailed above and then
washed with assay buffer. Neutrophils (0.3 
 
3
 
 10
 
6
 
) or assay buffer
were added to wells and incubated at 37
 
8
 
C for 10 min. Wells
were washed twice with DPBS, and then fixed with methanol
(
 
2
 
20
 
8
 
C) on ice for 5 min, followed by three washes. Immunoflu-
orescence staining was performed as detailed (23). Fields of FITC
fluorescence–stained EC were visualized on a fluorescence mi-
croscope (Microfot FXA; Nikon, Inc., Melville, NY) equipped
with a 
 
3
 
20 objective and the images were captured using a
cooled charged-coupled device video camera. Exposure times
were matched in each instance (typically 1–3 s, final magnifica-
tion of all images was 320, except where noted).
 
Immunoprecipitation of Endothelial Proteins
and Immunoblotting
 
Immunoprecipitation of Junctional Proteins.
 
VE–cadherin com-
plex proteins were immunoprecipitated using a modification of
the method of Lampugnani et al. (8). In brief, EC were incubated
with inhibitors, ALLM, or carrier (0.02% DMSO) and/or TNF-
 
a
 
,
and then washed three times with assay buffer. EC were incu-
bated at 37
 
8
 
C for 10 min under static conditions with either 10
 
7
 
human neutrophils (5 ml, ratio of neutrophils to EC was 2.5:1) or
assay buffer alone. Nonadherent neutrophils were removed by
washing (2 times) the monolayers with DPBS alone. Plates were
placed on ice and the Triton X-100 soluble fraction extracted for
30 min in lysis buffer (10 mM Tris, 150 mM NaCl, 1 mM PMSF,
40 U/ml aprotinin, 15 
 
m
 
g/ml leupeptin, 0.36 mM 1,10-phenan-
throline, 2 mM CaCl
 
2
 
 (Tris-buffered saline [TBS] and protease
inhibitors), 1% NP-40, and 1% Triton X-100), mixing every few
minutes. For total lysates, monolayers were lysed in lysis buffer
containing 0.5% SDS. The supernatant was collected, microcen-
trifuged at 14,000 
 
g
 
 for 5 min, and stored at 
 
2
 
80
 
8
 
C. The lysed
monolayers were washed 3 times with TBS and protease inhibitors,
and the Triton X-100 insoluble fraction was extracted as detailed
(8) and stored at 
 
2
 
80
 
8
 
C.
For immunoprecipitation, protein G–Sepharose was washed with
TBS, and a 60-
 
m
 
l suspension (1:1 suspension with TBS) was cou-
pled to mAb by mixing for 1 h at ambient temperature with 8–10 
 
m
 
g
of one of several mAb in a final volume of 500 
 
m
 
l. The above
concentrations of mAbs were optimal for detection in our system.
The IgG protein G–Sepharose was microcentrifuged and washed
(3 times) with TBS containing 1 mM PMSF, 40 U/ml aprotinin,
1 mM CaCl
 
2
 
, and 2% (vol/vol) Triton X-100 (buffer 1). The cell
lysates (representing 0.5–1 
 
3 
 
10
 
6
 
 EC) were precleared by incu-
bating with protein G–Sepharose, pelleted, and the supernatants
were incubated with the IgG protein G–Sepharose for 1 h at RT.
The immunoprecipitates were then washed (3 times) with TBS
containing 1 mM PMSF, 40 U/ml aprotinin, 0.05% (vol/vol)
NP-40, and 2 mM CaCl
 
2
 
, and boiled for 5 min in 2
 
3
 
 sample
loading buffer. The entire supernatant of samples was resolved by
SDS-PAGE (24) on a 7.5% (wt/vol) polyacrylamide gel and
transferred to nitrocellulose membrane (Hybond; Amersham Corp.,
Arlington Heights, IL).
 
Immunoblot Analysis.
 
Immunoblots were performed using a
modification of the method of Donnelly et al. (25). The membrane
was blocked for 1 h with 5% dried milk protein in PBS (blocking
buffer) and then incubated for 2 h with primary mAb (either 5
 
m
 
g/ml anti–VE–cadherin, 1 
 
m
 
g/ml anti–
 
a
 
-catenin, anti–
 
b
 
-cate-
 
Table 1.
 
Effects of Proteasome Inhibitor Lactacystin on EC Expression of Adhesion Molecules.
 
Treatment E-selectin ICAM-1 VCAM-1 p96
None 13 
 
6 
 
22 29 
 
6 
 
32  
 
6 
 
3 500 
 
6 
 
10
1 h carrier; TNF-
 
a
 
 4 h 272 
 
6 
 
29‡ 239 6 3‡ 253 6 8‡ 488 6 28
1 h Lac; TNF-a 4 h 72 6 7§ 72 6 3§ 72 6 8§ 432 6 42
1 h ALLM; TNF-a 4 h 232 6 45‡ 220 6 3 247 6 18 428 6 18
TNF-a 4 h; carrier 2 h 235 6 73 334 6 20 352 6 9 444 6 42
TNF-a 4 h; Lac 2 h 237 6 19 350 6 4 334 6 22 498 6 45
TNF-a 4 h; ALLM 2 h 245 6 20 351 6 17 343 6 8 465 6 45
*Surface expression of adhesion molecules was determined using a two-step indirect surface immunofluorescence assay (19) and the mAb listed in
Materials and Methods. Aliquots of lactacystin (Lac, 10 mM) and calpain inhibitor II (ALLM, 40 mM) were thawed and immediately diluted into
culture media to final concentration of 20 mM. Carrier control was 0.02% DMSO. The results are the average of triplicate wells and are representa-
tive of two separate experiments. Background nonbinding control mAb K16/16 was 6 6 4.
‡Value is significantly higher (P ,0.05) than media control of unactivated EC monolayers
§Value is significantly lower than carrier TNF-a–activated EC monolayers (P ,0.01).520 Endothelial Regulation of Neutrophil Transmigration
nin or anti-p120, or 5 mg/ml anti-plakoglobin or anti–PECAM-1
diluted in block). The membrane was washed six times at 5 min
intervals with PBS containing 0.05% (vol/vol) Tween 20 and
0.05% (wt/vol) BSA Tween 20, and then the primary mAbs were
detected with anti–mouse IgG conjugated to horseradish peroxi-
dase (Sigma Chemical Co., 1/10,000 dilution, 1 h at room tem-
perature). The immunoreactive bands were visualized using en-
hanced chemiluminescence (Amersham Corp.).
Statistics
Adhesion data was collected by analyses of variance and Stu-
dent’s two sample t test was used to calculate statistical signifi-
cance (Minitab Software, State College, PA).
Results
Lactacystin Inhibits Neutrophil Transendothelial Migration.
We have found previously that pretreatment of endothelial
monolayers with the aldehyde peptide 20S proteasome in-
hibitor MG132 before TNF-a activation of EC dramati-
cally reduces the induction of E-selectin, ICAM-1, and
VCAM-1 gene transcription (4). Functionally, this results
in reduced neutrophil and lymphocyte adhesion and inhi-
bition of transendothelial migration under flow conditions.
Lactacystin (13) is a Streptomyces metabolite that potently
inhibits the 20S proteasome, and is structurally distinct from
MG132 (4). Pretreatment of EC with lactacystin (20 mM)
before TNF-a also significantly inhibited surface expression
of adhesion molecules (Table 1), reduced adhesion by 88%,
and essentially ablated neutrophil transmigration (.95% in-
hibition).
To distinguish between the effects of the proteasome in-
hibitors on expression of endothelial leukocyte adhesion
molecules and the process of neutrophil transmigration,
MG132, lactacystin, or carrier control were added to 4 h
TNF-a–activated EC, and the monolayers further incu-
bated. Under such conditions, both inhibitors have no ef-
fect on neutrophil adhesion (Fig. 1) or expression of endo-
thelial adhesion molecules (Table 1 and data not shown),
but reduce neutrophil transmigration by .50% (Fig. 1).
The effect on transmigration was observed by 60 min, and
by 120 min the level of blockade was .70% for MG132
and .60% for lactacystin. A direct effect of the inhibitors
on neutrophils is not likely because a 5-min pretreatment
of neutrophils with 5 mM MG132 before perfusion did not
alter neutrophil adhesion or transmigration (vehicle, 51.5 6
5.9% transmigrated versus MG132 treated, 51.5 6 6.3%; n 5
3 experiments). We conclude that MG132 and lactacystin,
two structurally distinct inhibitors of the proteasome, act
on the endothelium to block transmigration, separately from
their effect on adhesion molecule expression.
The Endothelial VE–Cadherin Complex Is Not Altered by
Treatment with TNF-a, Proteasomal Inhibitors, or Their Com-
bination. Inhibition of neutrophil penetration suggests
that the function of lateral junctions is an important endo-
thelial-dependent component(s) for transendothelial passage
of the leukocyte. To examine the effects of TNF-a, pro-
teasomal inhibitors or both on the VE–cadherin complex,
confluent EC monolayers were incubated with or without
inhibitors and then with or without TNF-a for a total of
6 h. The effect of these treatments on the VE–cadherin
complex was determined in Triton X-100–soluble lysates by
immunoprecipitation with anti–VE–cadherin mAb and im-
munoblot analysis using specific mAb, and by a second in-
dependent analysis using immunofluorescence photomi-
croscopy. VE–cadherin, a- and b-catenins, and plakoglobin
were clearly identified (Fig. 2, lane C), and their migration
in SDS-PAGE under reduced conditions was consistent with
previous reports (8, 12). Similarly, immunoprecipitation with
anti–VE–cadherin mAb, and subsequent immunoblotting
analysis with an anti-p120 mAb, detected a single band mi-
grating at 120 kD (data not shown), but the results were not
consistently found in every EC culture examined. How-
ever, analysis of EC lysates with anti-p120 mAb followed
by blotting with anti-p120 consistently revealed a band at
120 kD and a second band at 100 kD, consistent with a re-
cent analysis in endothelium derived from brain (12). The
endothelial VE–cadherin complex was not altered by 6 h of
incubation with TNF-a, MG132, ALLM, lactacystin, or
carrier control (Fig. 2, compare lane C with lanes T, MG,
Figure 1. Proteasome inhibitors MG132 and lactacystin prevent neu-
trophil migration under flow at 1.8 dynes/cm2. Confluent EC monolay-
ers were incubated with TNF-a for 4 h before addition of proteasome in-
hibitors (MG, 20 mM MG132; LAC, 20 mM lactacystin) or DMSO
carrier (Cont.) for 1 (left) or 2 h (right), and neutrophil adhesion and trans-
migration were assessed as detailed in Materials and Methods. *P ,0.05.
Figure 2. The endothelial
VE–cadherin complex is not al-
tered by incubation with protea-
somal inhibitors with or without
TNF-a treatment. Confluent
EC monolayers were treated
with inhibitors before or after
addition of TNF-a, washed
twice, and extracted in lysis
buffer 1 (Materials and Methods). The VE–cadherin complex was immu-
noprecipitated using anti–VE–cadherin mAb, separated by SDS-PAGE,
and subjected to immunoblotting using mAbs that recognize a- and
b-catenins, plakoglobin, and p120. The results with anti-p120 mAb were
variable and p120 was not always detected, even though the other com-
ponents shown were consistent and reproducible. The x-axis labels are:
C, 0.02% DMSO; T, 25 ng/ml of TNF-a for 4 h; MG, MG132 (20
mM) for 4 h; ALLM, ALLM (20 mM) treatment for 4 h.521 Allport et al.
and  ALLM; data with lactacystin not shown). Similarly,
treatment with TNF-a for 4 h followed by 2 h of coincu-
bation with inhibitors, ALLM, or carrier control did not al-
ter the VE–cadherin complex (data not shown).
Analysis of Triton X-100 cell lysates also revealed that
the majority of VE–cadherin and other members of the
cadherin complex remained in the Triton X-100–soluble
fraction, not in the cytoskeleton-associated Triton X-100–
insoluble lysate (data not shown), and this distribution was
not altered by any of the above treatments.
Results of the immunoprecipitation and immunoblots
were supported by data obtained from indirect immunoflu-
orescence photomicroscopy (Fig. 3). TNF-a, lactacystin,
MG132, or ALLM treatments alone, or incubations for 4 h
with TNF-a followed by 2 h incubations with either in-
hibitors or ALLM, had no effect on the localization of the
components of VE–cadherin complex to the lateral junc-
tions. The results suggest that treatment of confluent EC
monolayers with TNF-a or inhibitors, alone or in combi-
nation, does not alter the biochemical composition or lat-
eral junction localization of the VE–cadherin complex.
Neutrophil Adhesion/Transmigration Dramatically Disrupts
the VE–Cadherin Complex. To examine whether neutro-
phil transmigration correlated with any alterations in the
VE–cadherin complex, neutrophils were incubated with
TNF-a–activated EC monolayers for 10 min, and then the
nonadherent neutrophils were removed by washing. Vis-
ual  inspection of TNF-a–treated EC cultures before lysis
showed intact and tightly confluent monolayers with many
adherent and transmigrated neutrophils. The ratio of adher-
ent neutrophils to individual EC was 1:2. In contrast, few
neutrophils adhered to unactivated EC, and no neutrophils
transmigrated. When the levels of VE–cadherin complex
were determined in Triton X-100–soluble lysates by im-
Figure 3. Colocalization of VE–cadherin, plakoglobin, and p120/p100 to lateral cell-to-cell junctions in confluent EC monolayers is not altered by
TNF-a alone or TNF-a plus MG132. Confluent cultured EC were treated with carrier (0.02% DMSO), TNF-a (4 h), or TNF-a (4 h) followed by 2 h
of incubation with MG132 (20 mM), washed, and fixed on ice with cold methanol for 5 min. Complex components were detected using specific mAb as
detailed in Materials and Methods.522 Endothelial Regulation of Neutrophil Transmigration
munoprecipitation with anti–VE–cadherin mAb and im-
munoblotting with specific mAb to each component, dra-
matic alterations were observed. Neutrophil adhesion and/or
migration across TNF-a–activated EC monolayers induced
loss of VE–cadherin, b-catenin, and plakoglobin, whereas
the level of a-catenin was not decreased (Fig. 4 A, com-
pare lane 3 to 4). Over the course of our experiments, we
noted that the native immunoreactive species of b-catenin,
plakoglobin, and p120/p100 were always below detectable
levels, whereas there was often retention of a small amount
of VE–cadherin. Coincubation of control unactivated EC
monolayers with unactivated neutrophils consistently had no
significant effect on the VE–cadherin complex (compare
lane 1 and 2). Since equal numbers of EC were used for
each sample, and this ECL detection system is very sensi-
tive, we infer the losses are not due to unequal sample
loading.
Neutrophil Adhesion Induces Rapid Disruption and Degrada-
tion of VE–Cadherin Complex. The disruption of the VE–
Cadherin complex by addition of neutrophils was accom-
panied by significant loss and proteolytic cleavage of each
component, except a-catenin. This was addressed by using
total EC monolayer lysates (soluble in 1% Triton X-100,
1% NP-40, and 0.5% SDS) and performing immunopre-
cipitation with specific mAb directed against each compo-
nent. Immunoprecipitated proteins were detected subse-
Figure 4. Effect of neutrophil adhesion on the endothelial VE–cad-
herin complex. (A) Confluent EC monolayers were incubated with me-
dia alone or media containing TNF-a for 6 h and washed. Neutrophils
(107) in DPBS-HSA or DPBS-HSA alone were added for 10 min at 378C
under static conditions. Nonadherent neutrophils were removed by
washing and the monolayers were extracted on ice for 30 min. Proteins
were immunoprecipitated with anti–VE–cadherin mAb as detailed in
Materials and Methods and detected by immunoblotting with specific
mAb. (B) Confluent EC monolayers were treated with media alone or
media containing TNF-a for 4 h, washed twice, and 107 neutrophils
were added. After incubation for 0, 3, or 10 min at 378C, nonadherent
neutrophils were removed, and monolayers were extracted with lysis
buffer 1 containing 0.5% SDS. Proteins were immunoprecipitated using
specific mAb directed against each individual component and subse-
quently detected by immunoblotting with a specific mAb. The Mr for
molecular mass standards are shown on the left margin and 0, 3, and 10
refer to the time period of neutrophil–EC coincubation at 378C. (C) Me-
dia alone (lane 1), resting neutrophils (107 cells, lane 2), neutrophil mem-
branes representing 107 cells (lane 3), or conditioned media from coincu-
bations of neutrophils (107 cells) with TNF-a–activated HUVEC (lane 4)
were added to control (lane 1) or TNF-a–activated HUVEC monolayers
(lanes 2–4) and incubated at 378C for 10 min. HUVEC were washed
twice and extracted with ice-cold lysis buffer 1 (without 0.5% SDS). Pro-
teins were immunoprecipitated with anti–VE–cadherin mAb as detailed
in Materials and Methods, and detected by immunoblotting with specific
mAb. (D) Neutrophil membranes representing 3 3 106 cells were incu-
bated with 4 h TNF-a–activated EC in wells of chamber slides for 10
min at 378C. The monolayers were washed twice and fixed for 5 min at
48C with ice-cold methanol. Junctional proteins were detected by indi-
rect immunofluorescence.523 Allport et al.
quently by immunoblotting with the same mAb. Addition
of SDS dissociates the complex from the cytoskeletal com-
ponents (8), and thus allows for determination of the total
cellular content (soluble and cytoskeletal-associated) of each
component of the complex. Total lysates were prepared
from EC treated with TNF-a and incubated with media
alone or media with neutrophils for 0, 3, or 10 min (Fig. 4
B, lanes 0, 3, and 10, respectively, for each mAb listed). In
parallel, adhesion and transmigration was assessed by phase
contrast microscopy. The levels of native b-catenin, VE–
cadherin, plakoglobin, and p120/p100 were decreased dra-
matically in TNF-a–activated EC coincubated with neu-
trophils for 3 min, a time point when neutrophil adhesion,
but no transmigration, had occurred. By 10 min, when many
neutrophils had adhered and transmigrated, the levels of each
component, except a-catenin, was reduced dramatically or
undetectable (Fig. 4 B, lanes labeled 10). The level and ap-
parent Mr of a-catenin was stable at each time point. These
results are consistent with the immunoblots of the VE–cad-
herin complex shown in Fig. 4 A. In contrast, PECAM-1,
which has been demonstrated to localize to endothelial
cell-to-cell lateral junctions and is involved in neutrophil
migration (15), remained at similar levels at both 0 and 10
min.
Inspection of immunoblots of total lysates (Fig. 4 B) from
TNF-a–activated EC coincubated with neutrophils using
anti–VE–cadherin mAb revealed the native VE–cadherin
species (140 kD, Fig. 4 B, large arrow, VE–cadherin, lane 0),
and  two immunoreactive bands with an apparent Mr of
z100 kD (small arrow) after 3 or 10 min. That a-catenin re-
mains associated with VE–cadherin, as demonstrated in Fig.
4 A, may be due to its continued association with these
100-kD VE–cadherin immunoreactive degradation products
identified in Fig. 4 B. Previous studies have reported that
a-catenins can associate directly with VE–cadherin in some
cells types (26), but not in others (27). Immunoblots of total
lysates with mAb to b-catenin revealed an immunoreactive
degradation product at z75 kD, and essentially total loss of
immunoreactive bands for p120/p100 and plakoglobin.
These data rule out the possibility that components of the
VE–cadherin complex shift their distribution from Triton
X-100–soluble to –insoluble fraction (i.e., cytoskeletal as-
sociated) after neutrophil adhesion. From these findings,
we infer that neutrophil adhesion alone is sufficient to in-
duce rapid endothelial-dependent disruption and partial
degradation of members of the VE–cadherin complex.
We then performed several experiments to show that
neutrophils trigger an endothelial-dependent signal that
leads to degradation of specific members of the complex.
First, the members of the VE–cadherin complex were clearly
disrupted after a 10 min coincubation of TNF-a–activated
EC with neutrophil membranes (representing 107 neutro-
phils, Fig. 4 C, lane 3), which are devoid of granule con-
tents and had only residual elastase activity (0.38% of total
elastase activity when compared to intact neutrophils). In
addition, disruption of the VE–cadherin complex by incu-
bation of EC monolayers with neutrophil membranes was
demonstrated by indirect immunofluorescence studies (Fig.
4 D). Thus, the components that triggered disruption of
the VE–cadherin complex are present in neutrophil plasma
membranes. This suggests that the degradation is not due to
nonspecific degradation via neutrophil granule proteolytic
enzymes. Second, transfer of conditioned medium from
coincubation of neutrophils with TNF-activated EC to
TNF-activated EC did not alter the VE–cadherin complex
(Fig. 4 C, lane 4), suggesting degradation is not induced by
a soluble factor. Lastly, neutrophil interactions specifically
trigger both the disruption and partial degradation of VE–
cadherin complex since incubation of EC monolayers with
EDTA, which released VE–cadherin from the lateral junc-
tions (Fig. 5 A), did not trigger degradation of VE–cad-
herin complex (Fig. 5 B). Taken together, these findings
suggest that the dissociation and cleavage of VE–cadherin
and its associated proteins are carefully controlled endothe-
lial-specific event(s) that are triggered by leukocyte contact.
Indirect immunofluorescence photomicroscopy supported
the findings that neutrophil adhesion induced loss of the
VE–cadherin complex at EC lateral junctions (Fig. 6; neu-
trophils are identified with arrows). TNF-a–activated EC
monolayers were incubated with or without human neu-
Figure 5. Chelation of extra-
cellular Ca21 by EDTA releases
the VE–cadherin complex from
the lateral junctions, but does not
trigger degradation. (A) HU-
VEC monolayers were washed
and incubated for 2.5 min with 3
mM EDTA in HBSS, and then
fixed for 5 min in ice-cold meth-
anol. VE–cadherin or PECAM-1 was detected by indirect immu-
nofluorescence as detailed in Materials and Methods, and the images
were captured using a cooled charged-coupled device camera. (B) Im-
munoprecipitation and blotting studies show that incubation with EDTA
does not induce cleavage of VE–cadherin. Confluent EC monolayers
were incubated with TNF-a for 4 h, and then washed twice with DPBS
and incubated in either HBSS (lane 1) or HBSS medium containing 3
mM EDTA for 2.5 (lane 2) or 5 min (lane 3) at 378C. VE–cadherin was
immunoprecipitated, resolved by SDS-PAGE, and subjected to blotting
as detailed in Fig. 3 legend.524 Endothelial Regulation of Neutrophil Transmigration
trophils for 5 min, fixed, and then stained with mAb to the
VE–cadherin complex. The loss is clearly demonstrated for
monolayers stained to detect VE–cadherin, b-catenin, p120/
p100, and plakoglobin, whereas the level and junctional
colocalization of PECAM-1 remained constant. A signifi-
cant overall reduction in immunoreactive staining of b-cate-
nin, p120/p100, and plakoglobin was observed in the pres-
ence of neutrophils, whereas VE–cadherin was lost specifically
from regions of neutrophil adhesion/transmigration (small
arrows). This is consistent with the immunoprecipitation
data where, in the majority of experiments, a small amount
of native VE–cadherin is retained, whereas other compo-
nents of the complex are not detectable.
To investigate whether the degradation of the VE–cad-
herin complex involved the cellular proteasome system, the
effects of proteasome inhibitors were evaluated. As shown
in Fig. 7, disruption of the VE–cadherin complex was not
prevented by 2 h of incubation with 20 mM lactacystin or
MG132, even though such treatments significantly reduced
transmigration (Fig. 1). For comparison, the components of
the VE–cadherin complex in TNF-a–activated EC re-
mained constant in the absence of neutrophils. In addition,
shorter incubations (5 or 30 min) with 50 mM MG132 did
not prevent neutrophil-dependent dissociation of the VE–
cadherin complex (data not shown). These findings estab-
lish that neutrophil adhesion triggers rapid EC-dependent
degradation of the VE–cadherin complex through an enzy-
matic pathway that appears to be independent of the pro-
teasome.
Discussion
 The current work demonstrates that neutrophil adhe-
sion to TNF-a–activated endothelial monolayers dramati-
cally alters the molecular composition and organization of
the endothelial cell VE–cadherin complex, which has been
implicated in maintenance of endothelial cell-to-cell adhe-
sion and cell-to-cytoskeletal integrity. Neutrophil adhesion
to confluent TNF-a–activated endothelial monolayers in-
duced rapid and near complete dissociation of b-catenin,
p120/p100, and plakoglobin from VE–cadherin and loss of
their lateral junction colocalization. Biochemical analysis of
TNF-a–activated EC monolayers using immunoprecipita-
tion and immunoblotting revealed that these proteins are
degraded rapidly through a proteolytic mechanism that is
dependent on the endothelium and does not involve gran-
Figure 6. Photographs show
VE–cadherin, b-catenin, p120/
p100, plakoglobin, and PECAM-1
staining patterns. Indirect immu-
nofluorescence microscopy shows
that TNF-a–activated EC mono-
layers express abundant levels of
VE–cadherin, b-catenin, p120/
p100, plakoglobin, and PECAM-1
at lateral junctions before neu-
trophil adhesion (left). After 10
min of neutrophil adhesion, the
lateral staining of VE–cadherin,
b-catenin, p120/p100, and plako-
globin is lost, whereas PECAM-1
is still abundantly expressed at
lateral junctions (right). Adher-
ent neutrophils are identified
(right,  arrows), and intact VE–cad-
herin junctional staining (top as-
terisks). Original magnification
was 320, except VE–cadherin
which was 640.525 Allport et al.
ule components of the neutrophil. In contrast, PECAM-1,
which is not associated directly with the VE–cadherin com-
plex, but does colocalize to the lateral EC junctions and is
involved in leukocyte transmigration (28), remained at con-
stant levels and retained lateral junction localization. Given
the rapid and specific cleavage of the components of VE–
cadherin complex by the endothelial cells, we suspected
that the cellular proteasome was involved. Surprisingly, two
different proteasome inhibitors, MG132 or lactacystin, did
not prevent dissociation or degradation of components of
the VE–cadherin complex, however, both inhibitors did
prevent .60% of neutrophil transmigration, specifically by
preventing neutrophil penetration of the lateral junctions.
Taken together, the results demonstrate that leukocyte ad-
hesion and transmigration across the vascular endothelium
is more complex than previously appreciated, and that neu-
trophil adhesion induces substantial alterations in structural
components of the adherens junctions that may allow for
subsequent transmigration of neutrophils.
The current finding that neutrophil coincubation with
TNF-a–activated EC disrupts the VE–cadherin complex as
early as 3 min demonstrates that neutrophil–EC adhesion,
rather than transmigration, is the initiating signal. As re-
ported in the text, visual inspection of monolayers consis-
tently showed that no transmigration had occurred at 3 min,
even though disruption and degradation of the VE–cad-
herin complex was easily detected (Fig. 4 B). These data
suggest engagement of adhesion molecules may be crucial
in triggering EC-dependent events, although signaling through
molecules not involved in adhesion is certainly possible.
This notion is further supported by the positive effects of
neutrophil membranes on the VE–cadherin complex. Ad-
ditional studies are necessary to elucidate the intracellular
signaling mechanisms underlying VE–cadherin complex alter-
ations.
The observed changes in the association of VE–cadherin
with cytosolic a-catenin, b-catenin, and plakoglobin after
leukocyte adhesion/transmigration is interesting in a few
respects. Using conditions to retain intact VE–cadherin com-
plex, a-catenin remains associated with the z100-kD frag-
ments of VE–cadherin, whereas b-catenin and plakoglobin
do not. This is somewhat unexpected since a-catenin does
not appear to associate directly with members of the cad-
herin family in most cells examined (29, 30). One explana-
tion is that the cleaved z100-kD fragments of VE–cad-
herin can associate directly with a-catenin, even though
VE–cadherin is not localized at the lateral junction. This is
not unreasonable since a-catenin has been reported re-
cently to stably associate with VE–cadherin in EC and in
Chinese hamster ovary cells transiently transfected with
VE–cadherin (26). Secondly, the immunoprecipitation and
blotting analyses strongly suggest that p120/p100 associates
with the VE–cadherin complex in confluent EC monolay-
ers. Although the association of p120/p100 with VE–cad-
herin complex was not observed in every EC culture, direct
immunoprecipitation from total EC extracts and immuno-
blotting with anti-p120 mAb consistently detected two
specific bands at 120 and 100 kD, which is in line with the
report of Staddon and co-workers (31). Moreover, both bio-
chemical and indirect immunofluorescence evidence showed
that neutrophil coincubation with activated EC rapidly led
to the degradation and loss of lateral junctional staining of
p120/p100. One possible explanation for the inconsistency
of immunoprecipitation experiments using anti–VE–cad-
herin mAb is that only a small fraction of the cytosolic pool
of p120/p100 associates with VE–cadherin, or that the as-
sociation fluctuates due to tissue culture conditions and
thus the signal is low relative to the VE–cadherin complex
signal. Staddon et al. (12) have reported that in Mardin-
Darby canine kidney epithelial cells, only 20% of the cyto-
solic pool of p120/p100 associates with b-catenin.
While this manuscript was being reviewed, Del Maschio
et al. (32) reported a similar effect of neutrophils on the
VE–cadherin complex in human EC monolayers. The cur-
rent work confirms that neutrophils induce rapid adhesion-
dependent alterations in the VE–cadherin complex, and ex-
tends these observations to show that (a) disruption and
degradation is endothelial-dependent and independent of neu-
trophil proteolysis and (b) independent of the endothelial
proteasome system. Interestingly, Del Maschio et al. de-
scribed significant retention of VE–cadherin while still de-
tecting dramatic loss of b-catenin and plakoglobin (essen-
tially equivalent to the data reported in Fig. 4). The reason
for this difference in the level of VE–cadherin retained at
EC junctions is not clear. It cannot be explained by a dif-
ference in buffers because we still detect a dramatic loss of
VE–cadherin and its components when using their buffer
system for neutrophil-EC coincubations (M199 with or
without 20% FCS), lysis, and immunoprecipitation.
The proteasome may play an important role in regulat-
ing endothelial–leukocyte interactions. If selective proteol-
ysis lies at the center of a diverse array of cellular processes,
then a question is what controls its timing. Resolving these
issues may be important in understanding the role of the
proteasome in leukocyte transmigration. How the protea-
somal inhibitors interfere with neutrophil transmigration is
not clear. Several possibilities can be considered. First, spe-
cific signal transduction events initiated by endothelial–leu-
kocyte interactions may require the ubiquitin–proteasome
Figure 7. Proteasome inhibitors do not prevent neutrophil-induced
disruption of the VE–cadherin complex. Neutrophils (107 in 5 ml) were
incubated with EC monolayers that were treated with TNF-a (4 h, 25
ng/ml) followed by 2 h of incubation with MG132 (M), ALLM (A), or
lactacystin (L), or 0.02% DMSO (2). After 10 min at 378C, EC mono-
layers were extracted with lysis buffer 1 and processed for detection of the
VE–cadherin complex.526 Endothelial Regulation of Neutrophil Transmigration
proteolytic pathway. The paradigm for this is well estab-
lished for several processes (13, 33). Second, the protea-
some may degrade key architectural components of the
junctional complex. The VE–cadherin complex is probably
not the target of these events. Endothelial–leukocyte inter-
actions could alter the activity of the endothelial protea-
some by altering the composition or by increasing the ac-
tivity of specific catalytic components of the proteasome
facilitating transmigration. Third, the proteasome inhibitors
may act indirectly by altering the activity of important pro-
cesses other than the proteasome. The structure–function
relationship between the inhibitors used in this study suggests
that this possibility is unlikely. Two structurally distinct
proteasome inhibitors, lactacystin and MG132, specifically
blocked leukocyte transmigration. A structurally homolo-
gous peptide aldehyde (ALLM), which inhibits cathepsin B
and calpain but is a much weaker inhibitor of the protea-
some, did not block transmigration. Collectively, these find-
ings distinguish the proteasome pathway rather than cathep-
sin/calpain-mediated protein degradation or processing as
an important step in leukocyte transmigration.
The Process of Leukocyte Transendothelial Migration. The
current report, and several previous studies, further expand
the notion that EC–leukocyte adhesion triggers EC-depen-
dent changes that correlate with leukocyte transmigration.
Huang et al. (34) showed that intracellular Ca21 gradients
in EC were coupled to transendothelial migration. Neutro-
phil adhesion to EC induced rapid and transient several fold
increases in cytosolic Ca21 concentrations ([Ca21]i), which
paralleled the time course of neutrophil transmigration across
cytokine-activated EC grown on human amnion prepara-
tions. Pharmacological clamping of [Ca21]i with an intra-
cellular Ca21 chelator, bis-(2-amino-5-methylphenoxyle-
thane-N,N,N9,N9-tetraacetic acid tetraacetoxymethyl ester,
inhibited .90% of migration, but had no effect on adhe-
sion. Pfau et al., working with lymphocytes and EC (35),
and Zeigelstein et al., using both neutrophils and mono-
cytes interacting with endothelial monolayers under flow
conditions in vitro (36), also reported leukocyte adhesion–
dependent changes of [Ca21]i in EC and the leukocyte.
Neither of these studies report on the spatial resolution of
the Ca21 flux, so it remains to be determined whether the
cationic flux relates to an adhesion event or to a migratory
event. Thus, the role of increases of [Ca21]i in EC appear
compelling, whereas the relative role in leukocytes is less
clear. Interestingly, in a static assay system, pharmocologic
clamping of [Ca21]i in neutrophils did not dramatically alter
their migration across resting or cytokine-activated EC,
suggesting that changes in neutrophils [Ca21]i are not a pre-
requisite (37). In addition, Yoshida et al. (31) have reported
that binding of leukocytes to 4-h IL-1–activated EC induce
E-selectin linkage at its cytoplasmic domain to the EC actin
cytoskeleton. This link, or similar mechanisms, may supply
cues to the EC that influence downstream processes in-
volved in stable adhesion or in transmigration.
The results presented here raise several issues concerning
the function of lateral junctions during leukocyte traffick-
ing at sites of inflammation. A basic understanding of these
processes may lead to insight into therapies for prevention
of tissue damage and abnormal wound healing that occur as
a result of a pathological inflammatory response.
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